Back to Search
Start Over
The relationships between arsenic methylation and both skin lesions and hypertension caused by chronic exposure to arsenic in drinking water.
- Source :
-
Environmental Toxicology & Pharmacology . Jul2017, Vol. 53, p89-94. 6p. - Publication Year :
- 2017
-
Abstract
- The associations between arsenic exposure, arsenic methylation, and the prevalence of skin lesions and hypertension are investigated. The results indicate that the HS (hypertension and skin lesions) group and the S (skin lesions) group have higher urinary concentrations of iAs (inorganic arsenic), MMA (monomethylarsonic acid), DMA (dimethylarsinous acid) and%MMA, and lower SMI (secondary arsenic methylation index) compared to the H (hypertension) and N (without both hypertension and skin lesions) groups. The arsenic content in water which caused H may be lower than that which caused HS and S. In addition, the odds ratios suggest that higher urinary concentrations of iAs and MMA, %iAs, %MMA and PMI elevate the prevalence of only hypertension and skin lesions, and both hypertension and skin lesions. However, higher%DMA and SMI, and lower%MMA increase the prevalence of both hypertension and skin lesions compared to that of only skin lesions. It can be concluded that skin lesions subjects have higher prevalence of hypertension. Hypertension subjects may have higher prevalence of skin lesions. Lower%DMA and SMI, higher%iAs, %MMA and PMI enhance the prevalence of only hypertension and skin lesions, and both hypertension and skin lesions. Moreover, iAs and MMA may have higher toxicity and lead to both hypertension and skin lesions than to only hypertension. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ARSENIC
*METHYLATION
*HYPERTENSION
*DRINKING water
*CACODYLIC acid
Subjects
Details
- Language :
- English
- ISSN :
- 13826689
- Volume :
- 53
- Database :
- Academic Search Index
- Journal :
- Environmental Toxicology & Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 123974158
- Full Text :
- https://doi.org/10.1016/j.etap.2017.05.009